The abstract is read at the publisher; the summary is JClub's.
In children with type II/III pleuropulmonary blastoma, ctDNA carrying the tumor-specific DICER1 RNase IIIb hotspot was detectable in 85% of pretreatment samples and tracked tumor burden.
- Why it matters: Liquid biopsy targets are needed for early childhood lung cancer to monitor disease activity longitudinally and to identify response or recurrence without repeated invasive sampling.
- What they did: Using the International PPB/DICER1 Registry, blood was collected at clinical venous access timepoints; tumor sequencing defined each patient’s RNase IIIb hotspot, then personalized droplet digital PCR was used across 482 samples from 20 type I and 53 type II/III patients.
- The result: Pretreatment ctDNA burden was linked to tumor size (Spearman’s ρ=0.574, p=0.051), was absent after resection before chemotherapy (p<0.001), spiked 1–2 days after chemotherapy start, and during surveillance appeared a median of 5.3 weeks before clinical progression (p=0.001).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.